GPCR

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for obesity, supported by strong Phase 2b data. GPCR's $1.5B cash position and a projected cash runway through 2028 underpin its ability to execute pivotal trials and commercial plans. My SOTP analysis yields a fair value of $42.49/share, with aleniglipron's risk-adjusted NPV at $1.34B and pipeline assets included at no additional cost.

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses ​of the drug.

Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.